$7.31 15%
DNA Stock Price vs. AI Score
Data gathered: November 14

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming.


Ginkgo Bioworks Holdings
Price $7.31
Target Price Sign up
Volume 2,460,000
Market Cap $487M
Year Range $5.36 - $48.8
Dividend Yield 0%
Analyst Rating 25% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '2488M60M28M-56M-38M-1.080
Q2 '2456M136M-80M-217M-206M-4.400
Q1 '2450M83M-34M-166M-165M-0.080
Q4 '238.7M102M-93M-212M-165M-0.110
Q3 '2370M182M-112M-303M-265M-0.160

Insider Transactions View All

Coen Steven P. filed to sell 6,046 shares at $8.4.
October 8 '24
Dmytruk Mark E. filed to sell 30,237 shares at $8.4.
October 8 '24
Coen Steven P. filed to sell 5,609 shares at $6.2.
September 16 '24
Dmytruk Mark E. filed to sell 28,749 shares at $6.2.
September 16 '24
Dmytruk Mark E. filed to sell 1,088,186 shares at $0.3.
August 6 '24

What is the Market Cap of Ginkgo Bioworks Holdings?

The Market Cap of Ginkgo Bioworks Holdings is $487M.

What is the current stock price of Ginkgo Bioworks Holdings?

Currently, the price of one share of Ginkgo Bioworks Holdings stock is $7.31.

How can I analyze the DNA stock price chart for investment decisions?

The DNA stock price chart above provides a comprehensive visual representation of Ginkgo Bioworks Holdings' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Ginkgo Bioworks Holdings shares. Our platform offers an up-to-date DNA stock price chart, along with technical data analysis and alternative data insights.

Does DNA offer dividends to its shareholders?

As of our latest update, Ginkgo Bioworks Holdings (DNA) does not offer dividends to its shareholders. Investors interested in Ginkgo Bioworks Holdings should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Ginkgo Bioworks Holdings?

Some of the similar stocks of Ginkgo Bioworks Holdings are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.